Léna Guyon

Léna Guyon

Auto-generated profile, based on publicly available information

Léna Guyon

Université Caen Normandie, Normandie Univ, CERMN UR4258, F-14000 Caen, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Food Hydrocolloids
Verified
Journal Article
Closed access
TMThu H. McCann
Thu H. McCann
LGLena Guyon
Lena Guyon
PFPeter Fischer
Peter Fischer
LDLi Day
Li Day

20 November 2017 in Nano Research
Verified
Journal Article
Closed access
PDF file
LGLéna Guyon
Léna Guyon
ELElise Lepeltier
Elise Lepeltier
CPCatherine Passirani
Catherine Passirani
Peptide-based nanostructures have received much attention in the field of drug targeting. In fact, peptides have many advantages such as simplicity of the structure, biocompatibility, and chemical diversity. Moreover, some peptides, which are called cell-penetrating peptides, can cross cellular membranes and carry small molecules, small interfering RNA, or viruses inside live cells. These molecules are often covalently or noncovalently linked to cargoes, thus forming amphiphilic conjugates that can self-assemble. Supramolecular nanostructures formed from peptides are used in nanomedicine as a carrier to protect a drug and to target cancer cells. This review explores aliphatic-chain–conjugated peptides and drug-conjugated peptides that can self-assemble. Special emphasis is placed on the synthesis procedure, nanostructure formation, and biological activity. Open image in new window

27 November 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LGLéna Guyon
Léna Guyon
AGAnne-Claire Groo
Anne-Claire Groo
AMAurelie MALZERT-FREON
Aurelie MALZERT-FREON

14 October 2019 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
LGLéna Guyon
Léna Guyon
ELElise Lepeltier
Elise Lepeltier
JGJean-Christophe Gimel
Jean-Christophe Gimel
BCBrice Calvignac
Brice Calvignac
FFFlorence Franconi
Florence Franconi
CPCatherine Passirani
Catherine Passirani

6 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LSLine Séguy
Line Séguy
LGLéna Guyon
Léna Guyon
MMManon Maurel
Manon Maurel
PVPascal Verdie
Pascal Verdie
ADAudrey DAVIS
Audrey DAVIS
AMAurelie MALZERT-FREON
Aurelie MALZERT-FREON
Background and Purpose: The activation of 5-HT4 receptors with agonists has emerged as a valuable therapeutic strategy to treat Alzheimer’s disease (AD) by enhancing the nonamyloidogenic pathway. Here, the potential therapeutic effects of tegaserod, an effective agent for irritable bowel syndrome, were assessed for AD treatment. To envisage its efficient repurposing, tegaserod-loaded nanoemulsions were developed and functionalized by a blood–brain barrier shuttle peptide. Results: The butyrylcholinesterase inhibitory activity of tegaserod and its neuroprotective cellular effects were highlighted, confirming the interest of this pleiotropic drug for AD treatment. In regard to its drugability profile, and in order to limit its peripheral distribution after IV administration, its encapsulation into monodisperse lipid nanoemulsions (Tg-NEs) of about 50 nm, and with neutral zeta potential characteristics, was performed. The stability of the formulation in stock conditions at 4 °C and in blood biomimetic medium was established. The adsorption on Tg-NEs of peptide-22 was realized. The functionalized NEs were characterized by chromatographic methods (SEC and C18/HPLC) and isothermal titration calorimetry, attesting the efficiency of the adsorption. From in vitro assays, these nanocarriers appeared suitable for enabling tegaserod controlled release without hemolytic properties. Conclusion: The developed peptide-22 functionalized Tg-NEs appear as a valuable tool to allow exploration of the repurposed tegaserod in AD treatment in further preclinical studies.

15 July 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
LSLine Séguy
Line Séguy
LGLéna Guyon
Léna Guyon
SCSophie Corvaisier
Sophie Corvaisier
MMManon Maurel
Manon Maurel
PVPascal Verdie
Pascal Verdie
AMAurelie MALZERT-FREON
Aurelie MALZERT-FREON
Tegaserod is a serotonin receptor agonist with potential neuroprotective properties for Alzheimer's disease. Due to its low druggability profile and to avoid detrimental side effects, a brain-targeted formulation is required. Nanocarriers targeting the blood-brain barrier (BBB) with a shuttle peptide, such as peptide-22, or enabling direct nose-to-brain delivery were considered as valuable approaches. This study aimed to compare two types of lipid-based nanocarriers and determine the best formulation for intravenous (IV) or intranasal (IN) administration. Tegaserod-loaded nanoemulsions and liposomes were successfully developed, improving the solubilization of tegaserod in injectable formulations. Their properties were optimized for the IV route, and the two formulations were compared in terms of granulometric properties, stability, stealth properties, and transport across a human model of the human BBB. Based on these evaluations, peptide-22-decorated tegaserod-loaded nanoemulsions were the most promising for IV administration. In addition, tegaserod-loaded nanoemulsions or liposomes were incorporated in a gelling formulation with properties optimized for the IN route, focusing on gelation temperature, osmolarity, and pH. Due to its rheological profile and behavior at room temperature, gel-embedded liposomes emerged as the most suitable formulation for the IN route. The successful development of these nanocarriers will facilitate further preclinical evaluation of tegaserod in Alzheimer's disease.